Render Target: SSR
Render Timestamp: 2024-09-20T07:02:48.516Z
Commit: c4b931215f8ed52e59fa950853eadce9550a8bd5
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human Fms-related Tyrosine Kinase 3 Ligand (hFLT3L) #8924

This product is discontinued

Inquiry Info. # 8924

Please see our recommended alternatives.

    Product Information

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hFLT3L. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

    Storage

    Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 24
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hFLT3L. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg hFLT3L.
    Activity The bioactivity of recombinant hFLT3L was determined in a cell proliferation assay using BAF3 cells transfected with FLT3. The ED50 of each lot is between 1.1 - 2.3 ng/ml.
    Molecular Formula Recombinant hFLT3L contains no "tags" and the nonglycosylated protein has a calculated MW of 18,037. DTT-reduced and non-reduced protein migrate as 24 kDa polypeptides due to glycosylation, with non-reduced having slightly greater mobility due to intramolecular cystines. The expected amino-terminal TQDCS of recombinant hFLT3L was verified by amino acid sequencing.

    Source / Purification

    Recombinant human FLT3L (hFLT3L) Thr27-Pro185 (Accession #BC126293.1) was expressed in human 293 cells at Cell Signaling Technology.

    Background

    FLT3L is produced by T cells and stromal fibroblasts (1,2). FLT3L targets many cell types including hematopoietic stem cells, B cells, T cells, dendritic cells, and NK cells (1,2). FLT3L in combination with other factors stimulates differentiation and proliferation of hematopoietic multipotent progenitors and promotes proliferation of NK cells and dendritic cell subsets. There are two splice variants of FLT3L. Both the integral membrane and soluble splice variants are biologically active (1). Binding of FLT3L to its cognate tyrosine kinase receptor, FLT3, activates STAT3 and STAT5 (1,3). FLT3L is being tested for its ability to stimulate anti-tumor immune response via stimulation of dendritic and NK cells.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.